Our data also point to the potential use of heparanase inhibitors like Roneparstat for targeting minimal residual disease (MRD) in myeloma patients, the idea being that inhibition of heparanase might interfere with reestablishment of a microenvironment, thereby preventing relapse. This evidence concerns the gene HPSE and plasma cell myeloma.